Onegene Biotechnology develops multi-specific protein-based drugs using its UniStac® enzyme-mediated protein-protein conjugation technology to target complex diseases such as liver fibrosis and cancer. The company addresses the limitations of traditional therapies by creating drugs that modulate multiple signals in the disease microenvironment, enhancing treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional treatments for complex diseases like liver fibrosis and cancer often fall short due to their inability to simultaneously modulate multiple disease signals. These therapies typically target single pathways, failing to address the intricate interplay of factors within the disease microenvironment. This limitation can lead to suboptimal efficacy and the development of resistance.
Solution
Onegene Biotechnology develops multi-specific protein-based drugs designed to address the limitations of single-target therapies. Their UniStac® technology enables enzyme-mediated protein-protein conjugation, facilitating the creation of drugs that can simultaneously modulate multiple signals within the disease microenvironment. This multi-modal approach aims to provide a more comprehensive and targeted treatment strategy for complex diseases. By targeting multiple pathways, Onegene's drugs seek to enhance treatment efficacy and overcome the limitations of traditional single-target approaches. The company's pipeline includes liver-directed treatments for advanced liver fibrosis and immune-activating drugs for anticancer therapy.
Target Audience
Onegene Biotechnology's primary target audience includes patients suffering from complex diseases such as liver fibrosis and cancer, as well as the healthcare providers who treat them.
Features
- UniStac® platform: Enzyme-mediated protein-protein conjugation technology for creating multi-specific drugs.
- Fast development: Eliminates the need for heterodimerization optimization.
- True plug-and-play: No limitations on modality selection.
- Manufacturability: High production yield for multi-specific proteins.
- OGB21502: Tetra-specific treatment for non-alcoholic steatohepatitis (NASH) addressing metabolic syndrome and NLRP3 inflammasome activation.
- OGB23501: Tri-specific approach for promoting T-cell based immune activation to regulate the tumor microenvironment (TME).